![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Sunday, September 24, 2017 2:22:59 PM
Part of my question was cost to bring it to market since they are cash starved
We have been trying to get in contact with the large pharmaceutical and healthcare companies but have not reached the C-suite yet, i.e. the decision makers. The staff below the decision maker level are no different than civil servants – don’t make waves and take chances and you will keep your cushy jobs. They are not the people that take chances. We have a plan to reach the decision makers, just be patient.
What we have announced is not as disruptive to the market as the patented complimentary feature to Insulin Dose Adjustment that we plan to announce within 45 days.
We will not need a partner to come in to market the ALRT platform. We will announce commencement of our global launch in due course. We expect this to come together in the fourth quarter. I have persevered to get us to a position to launch our platform without having to face heavy dilution. Any buyout will have to be at terms acceptable to me. Nothing will happen without my consent. I am the inventor and holder of the patented innovation which I am licensing to ALRT for nothing but will be cancelled if there is a hostile takeover at unacceptable terms. With control of 97.5% of Company on a fully diluted basis, any hostile action will also go nowhere. Why am I the holder of the patent? Simple, I paid for the patent application and it is my idea. Ultimately, protection of the shareholder values. Again, please be patient.
Yes, I plan to go big but the ride may be a roller coaster ride. Simply, OTC investors are not accustomed to managements trying to build real assets. That is why investing IR and staying current with filing was not high on our priorities. As I said we did not expect the type of reaction in the market with the Insulin Dose Adjustment announcement. We announced it because it is a material change and we have to share that with the public with zero expectations. I am very thankful for the support that we have received. That is why I have instructed the person in charge to get in touch with the SEC and work out a plan to bring us back to a current issuer. If investors are interested, we will support. If there is no investor interest, we will not waste time, money and energy. The higher the market cap, the stronger hand I will have to deal with the large pharmaceutical and healthcare companies. On the other hand, if the share prices stayed at $0.0001, it would be better for the shares not to be trading.
I do not know how much you have invested in the Company. My wife and I have invested more than $20 million and put in a lot of efforts without drawing a salary but pay lots of salaries to get the platform developed. We are very mindful and sensitive of investments made by the public. Otherwise, we could have wind up the Company a long time ago and kept the benefits all to ourselves. Having said that, we plan to enjoy healthy returns on our investment and more importantly our intellectual capital and share part of that success with the minority shareholders.
As you said I plan to go big. The potential market for the ALRT platform is for 440 million diabetes patients including the 60 million insulin dependent patients and in the world. 2.5% of the Company owned by the minority shareholders that serves a customer base of the above mentioned size will still represent a huge number.
Best
Sidney
Recent ALRTF News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/29/2023 12:53:49 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/28/2023 08:49:25 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/10/2023 09:15:16 PM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM